Sign In
Buy GLP
$48.63
+0.410 (+0.85%)
At Close: Jul 28, 2026
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update
04:05pm, Thursday, 26'th Mar 2026
- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapita
Novo Nordisk's FDA-Approved GLP-1s Now Available With Hims & Hers
12:00pm, Thursday, 26'th Mar 2026
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today announced that a broad assortment of Novo Nordisk's FDA-approved GLP-1 medications are available to eligible customers, incl
Should Value Investors Buy Global Partners (GLP) Stock?
10:42am, Thursday, 26'th Mar 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Novo Nordisk GLP-1 pipeline shows promise but oral drug trends give analysts pause
08:36am, Thursday, 26'th Mar 2026
Novo Nordisk (NYSE:NVO) has received a broadly neutral assessment from Deutsche Bank and Citi after a series of clinical and commercial updates, with both brokers flagging encouraging but not transfor
Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments
04:05pm, Wednesday, 25'th Mar 2026
Evaluating Potential to Preserve Muscle Mass Associated with Weight Reduction Announces Preclinical Study Initiation, Patent Filing and Publication of Independent Scientific Research SOLANA BEACH, Cal
3 Reasons Why Growth Investors Shouldn't Overlook Global Partners (GLP)
01:46pm, Wednesday, 25'th Mar 2026
Global Partners (GLP) possesses solid growth attributes, which could help it handily outperform the market.
Jefferies trims Novo Nordisk target as GLP-1 pricing erosion and oral Wegovy launch uncertainty cloud first quarter
12:17pm, Tuesday, 24'th Mar 2026
The broker retains its hold rating, warning that overall portfolio growth may stall even as the oral weight-loss pill gains traction Jefferies has trimmed its price target on Novo Nordisk (NYSE:NVO),
Lexaria's Oral GLP-1 Drug Strategy Validated by Industry
09:15am, Tuesday, 24'th Mar 2026
"The window to shape the oral GLP-1 market is open now
GLP-1 And Private Labels Are A Genuine Threat To General Mills But I May Buy This Dip
08:42am, Tuesday, 24'th Mar 2026
General Mills (GIS) is rated a soft buy as its valuation appears attractive after a prolonged decline, despite recent underperformance. GLP-1 appetite-suppressing drugs and rising private label popula
Are GLP-1 Drugs Becoming a Meaningful Revenue Driver for CAH Stock?
12:30pm, Monday, 23'rd Mar 2026
CAH sees GLP-1 drugs boost revenue growth, but margins lag as strong demand lifts volumes without significantly improving profitability.
Global Partners LP COO Sells Nearly $740000 Worth of Units
11:38pm, Saturday, 21'st Mar 2026
This gasoline distributor's stock has increased so far in 2026. But how will the current geopolitical tensions threatening oil supply affect its performance?
GLP-1 drugs are changing how Americans eat. Food companies are racing to catch up
08:00am, Saturday, 21'st Mar 2026
For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their businesses. About one in every eight U.S. adults is currently taking a GLP-
Lilly GLP-1 drug rivals Novo's pipeline treatment on gut side effects but throws up skin concern
07:15am, Friday, 20'th Mar 2026
New trial data complicates the competitive picture in the fast-growing obesity drug market Eli Lilly and Co's (NYSE:LLY) experimental weight-loss and diabetes drug retatrutide has shown a side-effect
India's weight-loss drug boom: Novo Nordisk talks about GLP-1 generics after patent expiry
03:23am, Friday, 20'th Mar 2026
The patent on semaglutide, found in Novo Nordisk's Ozempic and Wegovy weight-loss drugs, expired in India on March 20. Vikrant Shrotriya, managing director at Novo Nordisk India, talks about how gener
Is It Too Late to Buy Eli Lilly?
11:15am, Thursday, 19'th Mar 2026
Eli Lilly's Mounjaro and Zepbound are the leading drugs in the GLP-1 space. The company's GLP-1 success has resulted in a lofty valuation for the stock.
